Gene · 1132
CHRM4: cholinergic receptor muscarinic 4
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. CHRM4: cholinergic receptor muscarinic 4. Genes, record 1132. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/1132
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P08173 | Muscarinic acetylcholine receptor M4 | 479 | 38 | Ensembl, GeneID, HGNC |
Source UniProt
Patents30
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 41219 | P08173 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 929 | P08173 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 929 | P08173 | Espacenet |
| EP 4541896 A1 | 2025-04-23 | 267 | P08173 | Espacenet |
| JP 2025010185 A | 2025-01-20 | 267 | P08173 | Espacenet |
| JP 2024519329 A | 2024-05-10 | 2 | P08173 | Espacenet |
| JP 2024041871 A | 2024-03-27 | 10 | P08173 | Espacenet |
| JP 2024041871 A | 2024-03-27 | 11 | P08173 | Espacenet |
| JP 2023184465 A | 2023-12-28 | 267 | P08173 | Espacenet |
| WO 2023243495 A | 2023-12-21 | 267 | P08173 | Espacenet |
1 to 10 of 30
See all 30 patentsDrugs11
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| AFACIFENACIN | CHEMBL3545165 | Muscarinic acetylcholine receptor antagonist | ANTAGONIST | ChEMBL |
| DAROTROPIUM | CHEMBL2365940 | Muscarinic acetylcholine receptor antagonist | ANTAGONIST | ChEMBL |
| DAROTROPIUM BROMIDE | CHEMBL2308782 | Muscarinic acetylcholine receptor antagonist | ANTAGONIST | ChEMBL |
| GLYCOPYRRONIUM | CHEMBL1201335 | Muscarinic acetylcholine receptor inhibitor | INHIBITOR | ChEMBL |
| GLYCOPYRRONIUM TOSYLATE | CHEMBL3707243 | Muscarinic acetylcholine receptor inhibitor | INHIBITOR | ChEMBL |
| SOFPIRONIUM | CHEMBL3707224 | Muscarinic acetylcholine receptor inhibitor | INHIBITOR | ChEMBL |
| SOFPIRONIUM BROMIDE | CHEMBL3707223 | Muscarinic acetylcholine receptor inhibitor | INHIBITOR | ChEMBL |
| TERODILINE | CHEMBL363295 | Muscarinic acetylcholine receptor antagonist | ANTAGONIST | ChEMBL |
| TERODILINE HYDROCHLORIDE | CHEMBL539770 | Muscarinic acetylcholine receptor antagonist | ANTAGONIST | ChEMBL |
| XANOMELINE | CHEMBL21536 | Muscarinic acetylcholine receptor M4 agonist | AGONIST | ChEMBL |
1 to 10 of 11
See all 11 drugsTrials123
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07571148 | XANOMELINE | ClinicalTrials.gov | ||
| NCT07541378 | GLYCOPYRRONIUM | ClinicalTrials.gov | ||
| NCT07525375 | GLYCOPYRRONIUM | PHASE2 | ClinicalTrials.gov | |
| NCT07489911 | GLYCOPYRRONIUM | ClinicalTrials.gov | ||
| NCT07424404 | XANOMELINE | PHASE3 | ClinicalTrials.gov | |
| NCT07423546 | XANOMELINE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07414134 | GLYCOPYRRONIUM | ClinicalTrials.gov | ||
| NCT07379827 | XANOMELINE | ClinicalTrials.gov | ||
| NCT07288567 | XANOMELINE | PHASE3 | ClinicalTrials.gov | |
| NCT07284745 | XANOMELINE | PHASE3 | ClinicalTrials.gov |
1 to 10 of 123
See all 123 trialsNIH grants458
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | CHRM4 papers | Newest fiscal year |
|---|---|---|---|
| ZIADK075020 | Muscarinic acetylcholine receptor subtypes: physiological roles | 5 | 2025 |
| T32MH065215 | Postdoctoral Program in Functional Neurogenomics | 4 | 2025 |
| P30CA086862 | Cancer Center Support Grant | 2 | 2025 |
| R01MH062646 | Regulation of Signaling by mGluR5 | 2 | 2025 |
| R01NS031373 | Functions of Metabotropic Glutamate Receptor Subtypes | 2 | 2025 |
| R37NS034696 | Dopaminergic and Muscarinic Signaling in the Striatum | 2 | 2025 |
| ZIAHL005801 | Genome-wide analysis of chromatin modifications | 2 | 2025 |
| ZIAHL006030 | Epigenetic Regulation of T cell differentiation | 2 | 2025 |
| K12CA090628 | Paul Calabresi Program in Clinical/Translational Research at Mayo Clinic | 1 | 2025 |
| P01AI063302 | The intersection of innate and adaptive immunity to intracellular pathogens | 1 | 2025 |
1 to 10 of 458Source NIH's project files
See all 458 nih grantsPapers540
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Receptor Contribution Reallocation After Removal of Literature-Derived Weights: A Secondary Sensitivity Analysis of the Integrated Ki-DDD-TWAS Pipeline for Antipsychotic Lipid-Trait Prioritization. | Cureus | 2026 | 42540671 | PubTator, text mining | PubMed |
| The Design, Synthesis and Pharmacological Characterization of Potent Xanomeline-Based M1 and M4 mAChR Bitopic Ligands. | J Med Chem | 2026 | 42503676 | PubTator, text mining | PubMed |
| Uncovering G Protein-Coupled Receptors: Novel Targets and Biomarkers for Predicting Glioma Prognosis. | Ann Clin Transl Neurol | 2026 | 42163039 | PubTator, text mining | PubMed |
| b -Hurwitz numbers from refined topological recursion. | Math Ann | 2026 | 41841125 | PubTator, text mining | PubMed |
| Health risk analysis of micro-and nanoplastic exposure via the microbiota-gut-brain axis. | Front Immunol | 2026 | 41789083 | PubTator, text mining | PubMed |
| The genetic architecture of postoperative delirium after major surgery and its relationship with nonpostoperative neurocognitive conditions: A genome-wide association study. | PLoS Med | 2026 | 41770756 | PubTator, text mining | PubMed |
| Prevalence of Circulating Autoantibodies Against G-Protein-Coupled Receptors as Potential Biomarkers for Long COVID: Preliminary Investigations. | Int J Mol Sci | 2026 | 41751924 | PubTator, text mining | PubMed |
| The Muscarinic Acetylcholine Receptor in Dermal Papilla Cells Regulates Hair Growth. | Int J Mol Sci | 2026 | 41751811 | PubTator, text mining | PubMed |
| The "Immune Rebellion" from the Intestines to the Liver: A Vicious Cycle That Causes the Liver to Collapse. | Metabolites | 2026 | 41745575 | PubTator, text mining | PubMed |
| Distinct molecular pathways leading to dosage-dependent temozolomide resistance in GBM stem cells. | Cancer Cell Int | 2026 | 41736030 | PubTator, text mining | PubMed |
1 to 10 of 540
See all 540 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/1132
GET https://conductscience.org/api/genes/v1/1132/patents?page=2